aTYR PHARMA (ATYR) Non Operating Income (2018 - 2026)

aTYR PHARMA (ATYR) has 9 years of Non Operating Income data on file, last reported at $644000.0 in Q1 2026.

• Quarterly Non Operating Income fell 27.8% year-over-year to $644000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.3 million (down 10.43% YoY) and the FY2025 annual result came in at $3.5 million, down 9.97% from the prior year.
• Non Operating Income retreated to $644000.0 in Q1 2026, from $832000.0 in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $1.3 million in Q3 2023 to a low of $163000.0 in Q2 2022.
• A 5-year average of $801352.9 and a median of $852000.0 in 2024 frame the typical range for Non Operating Income.
• Annual changes were most pronounced in 2023 — Non Operating Income jumped 646.01% — and 2024, when it slumped 30.71%.
• Tracing ATYR's Non Operating Income over 5 years: stood at $427000.0 in 2022, then surged by 180.56% to $1.2 million in 2023, then dropped by 28.88% to $852000.0 in 2024, then declined by 2.35% to $832000.0 in 2025, then slipped by 22.6% to $644000.0 in 2026.
• The last three Non Operating Income figures came in at $644000.0 (Q1 2026), $832000.0 (Q4 2025), and $999000.0 (Q3 2025), per Business Quant data.